Speakers’ Presentations

DAY 1

SESSION 1: SURROGATE ENDPOINTS AND MRD

SESSION 2: CURRENTLY AVAILABLE DATA: HOW TO DEFINE THE OPTIMAL DATA
SET FOR VALIDATION?

DAY 2

SESSION 3 : THE REGULATORS’ VIEW

SESSION 4: MRD AS A SURROGATE ENDPOINT: WHAT IS BEYOND MM?